Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Capelle Aan Den Ijssel

17 clinical trials in Capelle Aan Den Ijssel, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Capelle Aan Den Ijssel at a glance
17
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

17 trials in Capelle Aan Den Ijssel

Open in trial search

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Rectal cancer

Recruiting

Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Appendicitis+4

Recruiting

Study on Using Gentamicin and Clindamycin to Prevent Abscesses After Surgery for Complicated Appendicitis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Amsterdam UMC Stichting

Embolism venous

Recruiting

Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Leiden University Medical Center

Rectal cancer

Recruiting

Study on Preserving the Rectum in Early-Stage Rectal Cancer Patients Using Oxaliplatin and Capecitabine with Radiation Therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Stichting Radboud universitair medisch centrum

Study on Morning vs. Evening Dosing of Tofacitinib for Patients with Rheumatoid or Psoriatic Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tofacitinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Sepsis

Recruiting

Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Dose-Reduced Oxaliplatin and Drug Combination Study for Older Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Leiden University Medical Center

Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Capelle Aan Den Ijssel

What the registry says about research in the country

01 Oncology - Colorectal Studies

Multiple innovative trials focusing on colorectal cancer treatment strategies, including research on liver metastases management and chemotherapy optimization for older patients.

  • Hepatic arterial infusion therapy
  • Dose-adjusted chemotherapy protocols
  • Post-surgical treatment approaches

Advanced research exploring both surgical and medical interventions for improved patient outcomes.

02 Hematology & Breast Cancer

Groundbreaking studies in multiple myeloma treatment protocols and innovative approaches for hormone receptor-positive breast cancer management.

  • Treatment-free interval assessment
  • CDK 4/6 inhibition strategies
  • Endocrine therapy optimization

Focus on developing personalized treatment strategies for better long-term outcomes.

03 Inflammatory & Autoimmune Conditions

Comprehensive research on rheumatoid arthritis management, investigating novel treatment timing and personalized therapeutic approaches.

  • Chronotherapy effectiveness
  • Tailored management protocols
  • Cost-effectiveness analysis

Emphasis on patient-centered outcomes and treatment optimization.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.